BIOLOGICAL ROLE OF OSTEOACTIVIN, A PROTEIN EXPRESSED BY TUMOR-CONDITIONED MACROPHAGES, IN THE PROCESSES OF TUMOR GROWTH AND TISSUE REPAIR by M. Liguori
 Dottorato in Medicina Sperimentale e Biotecnologie Mediche 
BIOLOGICAL ROLE OF OSTEOACTIVIN , A PROTEIN 
EXPRESSED BY TUMOR-CONDITIONED MACROPHAGES, 
IN THE PROCESSES OF TUMOR GROWTH  
AND TISSUE REPAIR 
  
 
 
Anno Accademico 2016-2017 
Elaborato di: Manuela LIGUORI                                                                   
Matricola: R10734                                                                                                   
Relatore: Prof. Massimo Locati                                                                       
Correlatore: Dott.sa Paola Allavena                                                                      
1 
 
INDEX 
 
 
ABSTRACT ............................................................................................................................................. 2 
INTRODUCTION ..................................................................................................................................... 4 
Macrophages: immunity and inflammation ..................................................................................... 4 
Macrophages in tumors .................................................................................................................... 7 
The tumor microenvironment .......................................................................................................... 9 
The extracellular matrix .................................................................................................................. 10 
ECM remodeling in the tumor microenvironment ......................................................................... 12 
The inflammatory tumor microenvironment: ................................................................................ 14 
Tumor-conditioned macrophages .................................................................................................. 15 
AIM...................................................................................................................................................... 19 
RESULTS .............................................................................................................................................. 20 
Production and regulation of Osteoactivin  in monocytes/macrophages:..................................... 20 
Biological role of Osteoactivin  ....................................................................................................... 24 
Mice of the DBA/2J strain lack functional Osteoactivin  ................................................................ 26 
Characterization of the monocyte/macrophage lineage in DBA/2J and DBA/2J Gpnmb+ ............ 27 
Osteoactivin  in the tumoral context .............................................................................................. 29 
In vitro characterization of engineered cell lines ........................................................................... 40 
DISCUSSION ........................................................................................................................................ 45 
MATERIALS AND METHODS ................................................................................................................ 52 
BIBLIOGRAPHY .................................................................................................................................... 58 
 
 
 
 
 
 
 
2 
 
ABSTRACT 
 
Tumor-Associated Macrophages (TAM) are key orchestrators of the tumor microenvironment, 
directly affecting neoplastic cell growth, neo-angiogenesis, extracellular matrix remodeling and 
immunosuppression. In a gene profiling analysis on tumor-conditioned macrophages cultured in 
vitro with tumor cell supernatants, we identified a number of up-regulated genes. One of the most 
expressed gene was Gpnmb, coding for a protein called Human Glycoprotein non-metastatic 
melanoma protein B (GPNMB), also named Osteoactivin  (OA). Osteoactivin  is a trans-membrane 
and shed molecule with diverse biological functions, spanning from cell adhesion and migration, to 
immune-suppression and tissue repair. This study investigates the modulation of this protein and its 
functional role in monocytes/macrophages and TAM, in the tumor context. In human monocytes, 
expression of OA is up-regulated by anti-inflammatory stimuli, in particular IL-10, and 
corticosteroids. Immunostimulatory cytokines (IFNγ, IL-1β) or LPS are not stimulating its 
production. Accordingly, in vitro M2-polarized macrophages express more OA than M1-
macrophages. 
A spontaneous mutation of the Gpnmb gene occurred in the DBA/2J mouse strain. The mutation 
causes a premature stop codon and generation of a truncated non-functional protein. This strain, 
and the reconstituted DBA/2J-Gpnmb
+
 mice with functional OA, are commercially available. OA-
defective mice do not have obvious major problems, with the exception of the known rapid onset of 
glaucoma.  
To clarify the role of this protein in the tumor microenvironment, we generated 
methylcolantrene-induced fibrosarcoma in these mice. Both mouse strains produced tumors with a 
similar incidence. We established and characterized 2 cell lines from DBA/2JGpnmb
+
 mice and 2 
from DBA/2J mice. Tumors from DBA/2J mice grew earlier in DBA/2JGpnmb
+
 mice, indicating 
that the protein Osteoactivin  produced by stromal cells, including TAM, enhanced tumor growth. 
To better understand the function of this protein, we generated isogenic cell lines expressing or not 
the functional OA protein (G2 OA and G2 MOCK cells). Osteoactivin -expressing cells grew faster 
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in vitro and under serum-free conditions were able to survive and to form spheroids which go on 
proliferating in an anchorage-independent manner. OA-expressing cells present typical cancer stem 
cell markers on their membranes such as Sca1, CD117 and SOX-2 and they are able to self-renew.  
The in vivo experiments demonstrated that Osteoactivin  expression is associated with a 
significantly more aggressive phenotype, both in terms of tumor-take and tumor growth compared 
to OA-defective cell lines.  We further demonstrated that OA-expressing tumors have higher 
mRNA levels of specific stem markers and in particular Nanog, SOX-2 and Brachyury.   
From these data we can speculate that the production of Osteoactivin  and its secretion by 
macrophages in the tumor microenvironment might be involved in the maintenance of cancer cell  
stemness and their proliferative potential. 
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INTRODUCTION 
 
Macrophages: immunity and inflammation 
 
The term “macrophage” comes from the Greek makros "large" and phagein "eat" and means 
“big eaters” and they were described for the first time in 1882 by Ilya Mechnikov [1].  
Macrophages are large mononuclear cells (approximately 25-50 um diameter) with an irregular 
shape and they present membrane protrusions that help them in their activity of phagocytosis of 
pathogens or particulate matter. They constitute the mononuclear phagocyte system and represent 
the “first immune response” because they are the first cells of the innate immune system to enter 
inflamed tissues where they defend the body against pathogens. Macrophages display a great 
functional heterogeneity because, in addition to their role as “defenders”, by secreting immuno-
stimulatory cytokines to boost adaptive immunity, they are also very important during 
embryogenesis, development and tissue repair after damage. [2]  
Macrophages originate from the hematopoietic stem cells which, under the influence of several 
cytokines such as IL-1, IL-6 and IL-3, give rise to the common myeloid progenitor granulocyte-
monocyte colony-forming units (GM-CFU). From this common progenitor, through different steps 
of differentiation, are derived both neutrophils and both monocytes, the latter specifically driven by 
the growth factor Macrophage-Colony Stimulating Factor (M-CSF).  However, recent evidence 
demonstrated that resident macrophages in peripheral tissues originate from hematopoietic 
precursors that were seeded during the embryonic development; few exceptions are the 
macrophages of specific sites such as the gastro-intestinal tract and the dermis [3, 4].   
Monocytes express on their surface large amounts of the marker CD14 (a component of the 
receptor sensing bacterial lipopolysaccharide, LPS). Human peripheral blood monocytes also 
differentially express other antigenic markers which may be functionally related to their 
physiological activities. In fact we can identify “inflammatory monocytes” through the expression 
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of CCR2
high
CD14
high
CD16
neg and “patrolling monocytes” that are CX3CR1highCD14dimCD16pos. In 
mice, monocyte subsets are defined by a set of slightly different markers: CCR2
high
Ly6C
high
 and 
CX3CR1
high
Ly6C
low
, for inflammatory and patrolling monocytes, respectively. During an 
inflammatory response, the former monocyte subset is rapidly recruited at injured tissues and 
differentiates into macrophages, while patrolling monocytes are considered important to re-
populate those peripheral tissues that are not dependent from embryonic precursors [3, 4]. 
In humans, in the peripheral circulation, mature monocytes constitute 5–10% of all blood 
leukocytes. The morphology of these cells can also be heterogeneous: they may have different size 
and degree of granularity and varied nuclear morphology [5, 6]  
Pro-inflammatory, metabolic and immune stimuli all elicit increased recruitment of monocytes 
to peripheral sites, where differentiation into macrophages or DCs occurs, contributing to host 
defense, tissue remodeling and repair. This process is strongly mediated by chemokines and 
chemokine receptors (for example CCL2 and its receptor CCR2, CX3CL1 and CX3CR1) that allow 
adhesion to endothelial cells and tissue entry [7, 8]  
The development of macrophages from monocytes is regulated by growth factors among which 
the most important is M-CSF, also called Colony Stimulating Factor (CSF1), guiding their 
differentiation as well as their proliferation and viability. A combination of different markers 
expressed on cell surface, such as CD68, CD14, CD16, CD11b and CD163 allows the 
identification of differentiated macrophages.  However, it has become increasingly clear that, 
depending on the local stimuli, macrophages could be activated in various ways, with profound 
changes in gene expression profiles [5, 6, 9].  
The current shared view about macrophage polarization considers dividing them in at least two 
general classes based on their phenotype and function: M1 (classically activated) and M2 
(alternatively activated). M1 macrophages are generated from monocytes stimulated with LPS and 
IFNγ; once differentiated they produce high levels of IL-12 , IL-1, IL- 23, TNFα and CXCL10,  
playing a fundamental role in the development of inflammatory processes: they have high 
microbicidal activity, immuno-stimulatory functions and are cytotoxic for tumor cells. These 
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macrophages can be identified from their surface antigens MHC II, CD80 and CD86 that are up-
regulated during M1 polarization [7, 10-12].   
On the other hand, M2 macrophages are critical effectors in parasitic infections and 
fundamentally contribute to tissue healing after injury by scavenging of debris, tissue remodeling, 
angiogenesis and resolution of inflammatory processes. They originate from monocytes 
differentiated in the presence of IL - 4, IL- 13, IL-10 or corticosteroids and, once mature, are able 
to secrete IL- 10, CCL17, CCL22, CCL18 and IL- 1ra. The M2 polarization is characterized by the 
over-expression of  CD206 (mannose receptor-1) on cell membrane, CD163 and other scavenger 
receptors [11].   
The loss of equilibrium of both M1 and M2 cell number may lead to pathological events: an M1 
excess could be the cause of chronic inflammatory diseases whereas an uncontrolled number of M2 
could promote immune suppression. [11, 13].  
However, due to the high heterogeneity of macrophages, it is now considered that the M1- and 
M2-polarization is an over-simplification and   just constitutes the two extremes of a wide panel of 
distinct phenotypes and functional states of the macrophages. Indeed, stimuli available in different 
pathological conditions, such as acute versus chronic inflammation, infection and cancer, activate 
distinct functional responses characterized by distinct transcriptional programs [12, 14, 15]. 
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 Macrophages in tumors 
 
Macrophages are a numerically abundant population in tumor tissues and it is now established 
that they contribute to the reactive environment, characterized by a low grade cancer-related 
inflammation [16-18] 
Macrophages in tumors derive from circulating monocytes, which are herein recruited by 
chemotactic factors, among which one of the most important is the chemokine CCL2 originally 
named Monocyte Chemotactic Protein 1(MCP-1) [19-21].   
In tumors, CCL2 can be produced by macrophages themselves as well as by stromal and cancer 
cells. Other important factors are the chemokines CCL5, CCL7, CXCL8 and CXCL12; the 
Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), M-CSF, but 
also fibronectin, fibrinogen and other factors produced during the cleavage of extra-cellular matrix 
(ECM) proteins elicited by macrophage- and/or tumor cell-derived proteases [11]. 
 
When blood monocytes migrate into tumor tissues they differentiate in Tumor-Associated 
Macrophages (TAM). TAM could represent up to 50% of the tumor mass, and operate as 
fundamental actors in the cross-talk between neoplastic and immune cells. There is now a general 
consensus that high TAM density in tumors is associated with faster disease progression and 
negative patient prognosis in several human neoplasms for example in lymphomas and in pancreas, 
breast and lung cancers. [6, 22-25] 
Within tumors, macrophages are in contact with different signals such as M-CSF that induces 
their differentiation, and other molecules that inhibit the M1 polarization, such as IL - 10 and 
TGFβ. Indeed, several studies have shown that TAM have similar characteristics as M2 polarized 
macrophages because they do not secrete high levels of inflammatory mediators, have pro-
angiogenic and immunosuppressive activity. [13]. However, the complexity of the tumor 
microenvironment and the low-grade inflammation often associated with cancer can induce more 
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nuanced or mixed phenotypes in TAMs, which show both inflammatory/anti-inflammatory and 
immunosuppressive characteristics [26]. 
Within the tumor microenvironment, macrophages can affect different fundamental aspects of the 
neoplastic population. For instance they promote tumor cell proliferation, via the production of 
growth factors (e.g. Epidermal Growth Factor, EGF); they support the mobility of cancer cells, 
favoring their invasion of surrounding tissues and distant metastatization. TAM accumulate in 
hypoxic areas within the tumor, where they stimulate angiogenesis by expressing several pro-
angiogenic factors and recruitment of other hematopoietic cells. Furthermore, TAM contribute to 
the buildup of the stromal matrix architecture by producing important components, including 
glycoproteins: osteopontin, fibronectin; proteoglycans: SPARC, different collagen types and 
proteolytic enzymes.  In collaboration with neoplastic cells, they can also influence fibroblasts by 
producing growth factors such as EGF, FGF, PDGF and, above all, TGFβ. In turn, activated 
fibroblasts release other biologically active mediators for epithelial cells (IGF, EGF, HGF), or 
macrophages (CCL2, CXCL12). 
 
 
Fig 1. Macrophage plasticity and TAM characterization. TAM functions are multiple and they include 
angiogenesis, metastatization, immunosuppression and support for cancer stem cell function.  [27] 
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The tumor microenvironment 
 
Solid tumors are composed by two different compartments: the parenchyma and the stroma that 
are often undistinguishable to each other [28, 29]. The parenchyma is made by cancer cells while 
the stroma includes various non-malignant cells types including fibroblasts, blood vessels and 
immune cells.  In the tumor microenvironment (TME) we can recognize: 
-Resident components: cells and structural factors that are stably present within the milieu of the 
stroma.  
-Non-resident components: immune cell populations that infiltrate the neoplastic 
microenvironment by extravasation through blood vessels; their recruitment is controlled by 
chemokines and factors produced by resident components.  
Various molecules are produced by these cells that are secreted into the extracellular space 
creating a very intricate network that support and sustain important activities of the tumor itself. 
This matrix is called extracellular matrix (ECM). 
 
 
Fig 2. Composition of tumor microenvironment. In addition to cells and structural factors stably 
present within the milieu of the stroma into tumor microenvironment we can find different cell populations 
such as MSC, myeloid cells, fibroblasts and various protein belonging to the extracellular matrix [30]. 
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The extracellular matrix 
The ECM is composed of a large collection of biochemically distinct elements including 
proteins, glycoproteins, proteoglycans and polysaccharides, with different physical and 
biochemical properties. All ECM elements appear aggregated to each other and to the surface of 
cells that produce them, in an organized compact network.  In the past it was thought that the ECM 
could serve as an inert scaffolding able to stabilize tissue structure, but it is now universally 
recognized that the ECM is functionally relevant and able to support cell adherence, migration, 
proliferation and differentiation, also influencing cell survival, shape and function [31]. The 
interaction between cells and extracellular matrix as well as composition/remodeling of ECM itself, 
can control physiological phenomena such as morphogenesis, pathophysiological events as wound 
healing, and pathological processes, like tumor invasion and metastatization  [32, 33]. 
 
 
 
Fig 3. Composition of the extracellular matrix. Collagen, fibronectin, polysaccharides are organized in 
a compact network. 
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The correct homeostasis between ECM deposition and degradation (matrix remodeling) is a 
complex and tightly regulated physiological process. Alteration in this homeostasis is relevant for a 
number of pathological events. For example, excess of ECM production or reduced ECM turnover 
are prominent in tissue fibrosis of many organs like pulmonary and renal fibrosis, systemic 
sclerosis, liver cirrhosis and cardiovascular disease. [34, 35]. Abnormal ECM dynamics are well 
documented also during tumorigenesis and metastatic progression of cancer. Various collagens, 
including collagen I, II, III, V, and IX, show increased deposition during tumor formation [36, 37], 
and increased MMP activity [38]. Moreover, many ECM components and their receptors, such as 
heparan sulfate proteoglycans and CD44, facilitate growth factor signaling and are frequently 
overproduced in cancer [39-41].  
The intense protease activation and ECM turnover in inflamed tissues are affected by cytokines, 
such as TGFβ, TNFα and IFNγ that are produced by inflammatory cells. Infiltrating immune cells 
release cytokines and proteases (e.g. MMPs) that in turn activate resident fibroblasts cells. This 
leads to an aberrant synthesis and/or cleavage of ECM components, contributing to the 
perpetuation of the inflammatory response towards the development of chronic inflammation [42]. 
ECM has an important role in influencing immune cell behaviour during the inflammatory 
process: the individual elements of the ECM and its three-dimensional structure can signal specific 
information to cells and modulate immune cell migration into and within inflamed tissues, immune 
cell activation and proliferation, and cell differentiation processes, such as T cell polarization [43].  
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ECM remodeling in the tumor microenvironment 
 
All tumors are characterized by their own heterogeneous and very dynamic microenvironment 
that evolves gradually along tumor growth, as a result of the tumor-host interaction. 
All the components of tumor microenvironment: cancer cells, non-cancer cells (endothelial 
cells, tumor-associated fibroblasts and immune cells, including macrophages), soluble factors 
(growth factors, cytokines, chemokines and proteolytic enzymes) take part in the intense 
remodeling and modification of the matrix that generates a microenvironment more and more 
suitable for tumor growth and progression. Nevertheless, macrophages within tumors are by far the 
main actors responsible for the constant transformation of  the tumor microenvironment [44]. 
Macrophages work through two important processes:  
1 ) The degradation of molecules present in the ECM activated or induced by neoplastic cells 
through specific proteases which can be grouped in large families and include matrix 
metalloproteases (MMPs), cathepsins, hyaluronidases, ADAM proteases, but also heparanase, 
elastase, urokinase-type plasminogen activator (uPA), plasmin and others, induced by neoplastic 
cells [45]; 
 2 ) The synthesis of new components of the ECM [46, 47]; 
ECM molecules have the ability to interact with cell surface receptors and with biological 
mediators such as cytokines, chemokines, growth factors and proteases. These interactions may 
profoundly affect cellular functions both on the tumor side as well as on the side of stromal, 
vascular and immune cells. Among the most important and mostly studied ECM molecules are: 
fibronectin, thrombospondin, osteopontin, collagens and SPARC (secreted protein acidic and rich 
in cysteine).  
Fibronectin (FN): is involved in many cellular processes, including cell migration and adhesion, 
tissue repair, blood clotting and embryogenesis. FN exists in two main forms: an insoluble 
glycoprotein in the ECM (extracellular matrix) and a soluble one present in the plasma. The ECM 
form is produced by fibroblasts, macrophages, endothelial and epithelial cells;  here FN organizes 
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interactions between various matrix components (proteoglycans) and different cells, via binding to 
specific  integrin receptors [48].  
Thrombospondins: are a family of secreted ECM proteins produced by several cell types in 
response to injury and during tissue remodeling; the thrombospondin family includes five members  
TSP-1, TSP-2, TSP-3, TSP-4, and TSP-5 [49]. 
Osteopontin: is a component of the ECM produced by stromal and tumor cells. In the tumor 
microenvironment osteoponting is involved in protease activation and ECM remodeling, cell 
adhesion and migration, angiogenesis, as well as in inflammation and immunity [50, 51].  
Collagens: are major components of the ECM and they represent about 30% of the total protein 
mass in the body. There are 28 different types of collagens which exist in fibrillar and non-fibrillar 
forms. Collagens can act as a scaffold, facilitating migration of invading cancer or stromal cells 
into ECM. 
SPARC (secreted protein acidic and rich in cysteine, also known as osteonectin): is a protein 
with the ability to bind to several resident components of the ECM such as  thrombospondin 1, 
vitronectin, entactin/nidogen, fibrillar collagens (types I, II, III, and V), and collagen type IV, 
modulating growth factor efficacy, affecting the expression of matrix metalloproteinases with an 
important contribute to the organization of ECM itself [52]. 
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The inflammatory tumor microenvironment:  
 
Cancer associated inflammation is now recognized as a hallmark of tumors[17]. Macrophages 
associated to the tumor microenvironment are the major source of inflammatory mediators, though 
a number of inflammatory cytokines can be produces also by cancer cells [16, 53]. 
As mentioned before, the interaction between neoplastic and immune cells is fundamental in the 
processes of tumorigenesis, tumor growth and metastasis. These processes are directly influenced 
by many growth factors and by pro-inflammatory as well as anti-inflammatory cytokines. These 
soluble or matrix-bound mediators constitute a very intricate network that allows the cross-talk 
between tumor, immunity and stromal cells[54].  
IL-6 is a pro-inflammatory cytokines that contributes to angiogenesis, promotes B and T cell 
differentiation and stimulates tumor cell proliferation [55]. Other pro-inflammatory factors derived 
from macrophages or other immune cells include IL-1β, TNFα and IFN-γ. 
Transforming growth factor beta (TGFβ) is a “double action” factor with both pro and anti-
tumorigenic activities; TGFβ can suppress growth or inhibit cancer progression activating the 
apoptosis process. It is also a strong inducer of the epithelial-to-mesenchymal cell transition 
(EMT), which can induce de-differentiation of cancer cells which acquire cancer stem-cell-like 
phenotype and motile phenotype. TGFβ is also a potent immune-suppressive factor [56]. 
Other inflammatory mediators include IL-10, a potent immunosuppressive factor that inhibits T 
cell-mediated tumor destruction and vascular endothelial growth factor (VEGF) which supports 
angiogenesis and inhibits DC function and migration.  Malignant transformation is often associated 
with aberrant production of FGF (fibroblast growth factor) and EGF (epidermal growth factor) 
which stimulate angiogenesis and proliferation of both tumor and stromal cells. [57, 58].  
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Tumor-conditioned macrophages 
 
Our group previously set up an in vitro model of co-culture between cancer cells and human 
monocytes, and selected those cell lines able to induce the differentiation of monocytes into 
macrophages. We next demonstrated that the cell lines with this biological activity were producing 
the growth and differentiation factor M-CSF, beyond other biological mediators. The phenotype 
and functional activity of these Tumor-Conditioned Macrophages (TC-Macro) differed from 
classically activated M1 macrophages and these cells were indeed more similar to M2 
macrophages. An Affymetrix gene profiling analysis of  TC-Macro and by comparison of  TAM 
isolated from human ovarian carcinoma revealed that indeed the TC-Macro are very similar to ex 
vivo human TAM, supporting the validity of our in vitro co-culture system [59]. Considering the 
gene expression analysis of TC-Macro, we found that among the most up-regulated genes were 
several genes coding for ECM proteins or related to its remodeling. Among proteolytic enzymes, 
the most expressed were MMPs (12, 9, 1 and 14), Cathepsins (L, C, Z and B), uPA, lysosomal 
enzymes and ADAM proteases. 
 
 
Fig 4. Gene profiling of human TAM. The scheme shows the expression of genes coding for ECM 
proteins end proteolytic enzymes implicated in its degradation/remodeling [47].  
 
Regarding matrix proteins we observed that Collagens, Osteopontin, GPNMB and Fibronectin 
were the most overexpressed genes. In particular we decided to focus our studies on GPNMB [59]. 
Glycoprotein non - metastatic melanoma protein B (GPNMB)  is a highly glycosylated type I 
transmembrane protein also named Osteoactivin  (OA). It was first described in 1995 as a protein 
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that shares significant sequence homology to melanosomal proteins: with the human protein and 
murine nmb (Non- metastatic melanomal protein B), with the protein PMEL 17, dendritic cell-
associated heparin sulfate proteoglycanintegrin ligand (DC-HIL) or hematopoietic growth factor 
inducible neurokinin-1 type (HGFIN) [60].  
The Gpnmb gene is localized to human chromosome 7 and mapped to mouse chromosome 6. 
The highly conserved Gpnmb gene consists of 11 exons with an open reading frame of 1716 bp  
and encodes for a protein of 572 amino acids. The protein consists of  an extracellular domain 
(ECD) that contains a signal peptide and a cleavage site at position 23 as well as a polycystic 
kidney disease (PKD) domain, 13 predicted N-linked glycosylation sites and an Arg-Gly-Asp 
(RGD) motif as integrin-binding site at position 556 and a cytoplasmic domain of GPNMB, called 
Osteoactivin , with a conserved di-leucin-based endosomal/melanosomal-sorting signal [60, 61].  
Osteoactivin  has two isoforms,  a transmembrane type I 65k -Da  isoform and a highly 
glycosylated secreted isoform 115k –Da. Osteoactivin   is expressed in a wide variety of human 
and mouse tissues and cell types such as melanocytes, endothelial cells as well as dendritic cells 
and macrophages . Within cells it is localized to the cell surface as well as into vesicular, 
endosomal- or lysosomal-like structures.  The secreted form is released by cells via ectodomain 
shedding. This process is regulated by protein kinase C as well as intracellular Ca2
+
-dependent 
pathways and it is mediated by MMPs and a disintegrin and metalloproteinase ADAM10 [62]. The 
cleaved form of Osteoactivin , which possesses the heparin-binding RGD motif, actually binds to a 
heparin sulfate proteoglycan-type receptor similar to the FGF receptor. It was furthermore shown 
that Osteoactivin  on the surface of dendritic cells can bind to endothelial cells via its RGD motif as 
well as to T cells via the PKD domain [63]. The interaction between dendritic cells and T cells is 
actually mediated by the binding of Osteoactivin  to syndecan-4 on T cells, which in turn leads to 
an inhibition of T cell responses[64].  In macrophages, the glycoprotein is present in the Golgi 
apparatus and was shown to be over-expressed  following interferon (IFN)-γ or lipopolysaccharide 
(LPS) treatment [65]. 
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The expression of Osteoactivin  in osteoblasts and melanocytes was shown to be regulated by 
the microphthalmia transcription factor (MITF) via a MITF-binding site (M-box) that is present in 
the Gpnmb promoter [66, 67].  In skeletal muscle cells after denervation, basic fibroblast growth 
factor (bFGF) and platelet-derived growth factor (PDGF) have been shown to regulate the 
expression of Osteoactivin  [68]. 
To  identify the biological functions of this protein has been challenging, both for the great 
variety of biological processes in which it appears to be involved, and for the contrasting results 
published in the literature. 
Osteoactivin  plays an important role both in physiological and pathological conditions. In fact 
it seems to have an important role in fibroblast differentiation, in the maintenance of bone 
homeostasis and in particular during growth and differentiation of osteoblasts / osteoclasts [69]. 
Osteoactivin  is furthermore essential for normal eye function: the protein is highly expressed in 
retinal pigment epithelium and iris during embryonic development. Studies using DBA/2J mice, 
which spontaneously underwent a premature stop codon mutation in the Gpnmb gene 
(GPNMBR150X), it has been demonstrated that these mice have pigment dispersing iris disease 
and subsequent age-related pigmentary glaucoma. The absence of Osteoactivin  mediates a 
melanosomal defect associated with cellular debris shedding in the eye chamber which consequent  
inflammation of the iris, atrophy and finally glaucoma [70, 71]. 
Osteoactivin  is up-regulated in several types of cancer. It  was described for the first time in 
low-metastatic human melanoma cell lines, but subsequent studies suggested that this protein is 
expressed by highly malignant tumors and promotes invasion and metastasis (with a correlation 
with over-expression of MMP-2/9 and MMP-3). Several studies also reported a high expression of 
Osteoactivin  in cutaneous melanomas,  in aggressive human breast cancers and other malignant 
tumors where it is able to induce cancer metastasis to bone [72, 73]. 
In addition, a number of studies demonstrated a pathophysiological role of Osteoactivin  in 
various disease models associated with inflammation and fibrosis. In skeletal muscle affected by 
denervation, Osteoactivin  was found to be up-regulated in myofibers and this might correlates with 
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an hypothetical role in  ECM regeneration and fibrosis. Osteoactivin  can interact with infiltrated 
fibroblasts, which in turn stimulates the expression of  MMP-3, MMP 9 and collagen I [74]. 
Another study by the same group demonstrated that the overexpression of the protein protects 
skeletal muscle from severe degeneration caused by long-term denervation in mice, accompanied 
by decreased infiltration of fibroblast-like cells, up-regulation of anti-fibrotic genes and lower 
levels of collagen deposition. In addition, the Osteoactivin  ectodomain shedding induces MMP-3 
expression in mouse fibroblasts through the activation of  the ERK pathway. The activation of 
ERK1/2 and p38 in the MAPK pathway may be involved in the attenuation of fibrosis [74]. In 
kidney, the protein was found to be strongly induced in tubular endothelium and interstitial 
fibroblasts after unilateral ureteral obstruction in rats with probable implication in regenerative 
processes and fibrosis upon injury. Moreover in monocytes and macrophages of mice after 
ischemic kidney disease there is an overexpression of Osteoactivin  which suggests the protein as a 
novel biomarker of progressive kidney disease using DBA/2J mice, Li and colleagues revealed that 
the absence of functional Osteoactivin  results in impaired phagocytosis and autophagy responsible 
for the degradation of internal debris and apoptotic cells [75]. This event led to higher mortality 
rates of these mice associated with increased apoptosis rates and prevention of normal organ repair. 
These results suggest that Osteoactivin  is involved in the repair after kidney damage by affecting 
macrophage function. All these results indicate that this protein plays an important role in 
inflammation, during fibrosis after injury in skeletal muscle, liver and kidney [65, 68, 76-78].  
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AIM 
 
The evidence that the Gpnmb gene coding for the protein Osteoactivin  was highly upregulated 
in tumor-conditioned macrophages (in vitro co-culture system of tumor cells and macrophages), 
prompted us to investigate the biological significance of this upregulation, especially in the 
connection between Tumor-Associated Macrophages and cancer cells. 
Aim of this study is to understand the biological role of Osteoactivin  produced by 
macrophages, in the context of the pro-tumor functions of these immune cells. 
In particular, we focused our attention on the regulation of this protein both in human and 
mouse phagocytic cells and on its biological role in the tumor microenvironment.  
For the in vivo study we took advantage of the mouse strain DBA/2J with a spontaneous non-
functional mutation in the Gpnmb gene. The Jackson Company generated a transgenic mouse line 
reconstituted with the native functional protein: DBA/2J-Gpnmb
+
 mice. Therefore, both mice with 
non-functional Osteoactivin  and mice with the functional protein were available for this study and 
greatly helped in the understanding of the biological function of Osteoactivin  in experimental 
tumor models. 
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RESULTS 
 
Production and regulation of Osteoactivin  in monocytes/macrophages: 
 
We previously demonstrated that Gpnmb is strongly upregulated (>85 fold) in tumor-
conditioned macrophages (TC-Macrophages), cultured with tumor cell supernatants [59]. 
In Fig 5 are summarized the results of the transcriptional profile analysis from our AffyData 
database. RNA was extract from monocytes freshly isolated from 3 different donors (Mono) and 
from in vitro M-CSF-differentiated macrophages (M0), further polarized to M1 and M2 cells; 
Gpnmb expression was very low in all monocytes analyzed (grey columns) while was greatly 
increased in their respective M0 and M2 polarized macrophages  (orange and purple columns 
respectively). Of note, M1 macrophages (pink coumns) had lower expression (Fig.5A).  
We also investigated Tumor-Associated Macrophages (TAM) isolated and purified from human 
ovarian carcinoma (green columns). Gpnmb mRNA levels were considerably elevated in human 
TAM (Fig.5B).  These results confirm our original observation obtained with  TC-Macrophages 
exposed  in vitro  to tumor cell supernatants (light blue columns) where Gpnmb is highly 
upregulated compared to monocytes cultured alone (Fig.5B). 
 
 
Fig 5. Transcriptional profile analysis of the Gpnmb gene in different human macrophage 
populations. A) Monocytes were freshly isolated from buffy coats and macrophages differentiated  from  
monocytes using  M-CSF for 6 days (M0)  and polarized with LPS and IFNγ (M1) or IL-4 (M2) for 24 hr.    
B) TC-Macrophages were cultured for 72 hrs  with tumor supernatants from the pancreatic cell lines PANC1 
or ASPC1; TAM were isolated from human ovarian carcinoma. Data are shown as hybridization signals from 
the Affymetrix chips. 
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In order to gain insights into the functional role of Osteoactivin  expression in 
monocytes/macrophages, especially in the tumor context, the first purpose of the thesis was to 
study the regulation of Osteoactivin  production in myeloid cells. 
For this purpose we evaluated Osteoactivin  protein expression in human and murine monocytes 
and macrophages in response to different stimuli and in the presence of distinct tumor cell 
supernatants. The transmembrane isoform of Osteoactivin  was investigated by flow cytometry 
with a commercial anti-Osteoactivin  mAb.  In human monocytes, Osteoactivin  expression was 
upregulated by the anti-inflammatory cytokine IL-10 and by glucocorticoids, but not by immuno-
stimulatory cytokines, such as IFNγ, or LPS, which actually repressed its expression (Fig 6).  
 
 
Fig 6. Modulation of the transmembrane isoform of OA in human monocytes. A) Flow cytometry 
analysis of the transmembrane form of OA in human monocytes treated with different stimuli for 24 hr. OA 
is up-regulated by anti-inflammatory stimuli (IL-10, glucocorticoids) and not by pro-inflammatory ones. Data 
are shown as fold increase over untreated monocytes (-), (mean -/+ SD of 3 exp);  the red line indicates the 
level beyond which our data are considered significant (1,5 F.I.). Statistical analysis: ∗p < 0.05, ∗∗p < 0.01, 
(Student’s t test). B) Representative phenotype profile of OA expression in glucocorticoids-treated 
monocytes (24h). The grey profile represents the control untreated cells; the black line represents the 
expression of Osteoactivin  in stimulated monocytes. 
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We next studied the soluble isoform by ELISA in TC-Macrophages and in polarized M1 and 
M2 macrophages. To generate tumor supernatants we used four different pancreatic tumor cell 
lines (PT45, PANC1, ASPC1 and MIaPaCa), an immortalized non-tumorigenic pancreatic cell line 
(HPDE) and an ovarian carcinoma cell line (K-ov). Human macrophages released Osteoactivin  in 
response to supernatants from PT45 and PANC1 cells but not when exposed to the other cell lines 
(Fig. 7A) , Of note, none of these cell lines constitutively produced this protein (data not shown).  
Osteoactivin  release from in vitro differentiated and polarized macrophages, surprisingly showed 
no significant difference between M0, M1 and M2 macrophages (Fig. 7A). In order to understand 
the kinetics of release, we analyzed monocytes treated with MSCF or tumor supernatants for 1, 3 
and 6 days.  Osteoactivin  release was very low at day 3 and much higher at day 6 (Fig 7B), 
indicating that the shedding requires some time to occur. 
 
Fig 7. Elisa quantification of the soluble form of human Osteoactivin  . A) Production of Osteoactivin   
in in vitro M-CSF-differentiated macrophages (M0), in M1/M2 polarized macrophages and in TC-
Macrophages. B) Kinetics of OA production over 6 days. Representative results from different experiments 
are shown. 
 
To confirm these data we repeated the above experiments with murine bone marrow-derived 
monocytes/macrophages. Unfortunately we have not found an antibody that worked so well for the 
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transmembrane isoform of murine OA; for this reason we could only evaluate the secreted form of 
the protein. We tested macrophage production of murine Osteoactivin  (mOA) by MCSF-
differentiated macrophages (M0), M1/M2 polarized macrophages, tumor-conditioned 
macrophages, as well as macrophages activated with LPS.  
To obtain murine TC-macrophages we generated tumor supernatants from the pancreatic murine 
tumor cell line (PANC02), the mastocytoma cell line (P815) and three murine fibrosarcoma cell 
lines (MN-MCA1, MCA-1 and MCA-2). From our data we observed that Osteoactivin  production 
was similarly induced in MCSF- macrophages, M1 and M2 macrophages, but was decreased in 
LPS stimulated ones (Fig 8A). Osteoactivin  is also induced in TC-macrophages, with higher 
production with supernatants from PANC02 cells and the fibrosarcoma MCA-2 and MN/MCA1 
(Fig. 8B). 
 
 
Fig 8. Elisa quantification of the soluble form of murine Osteoactivin . Production of osteoactivin  by 
murine bone marrow derived macrophages; A) M-CSF-differentiated macrophages, M1/M2 polarized 
macrophages (treated as detailed in legend of Fig.7) and LPS stimulated macrophages . B) Production of 
Osteoactivin   by murine tumor conditioned macrophages. Data are expressed as mean -/+ SD of 3 
experiments. Statistical analysis: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (Student’s t test). 
 
 
Overall, these results demonstrate that Osteoactivin is expressed in human and murine 
macrophages and its expression is increased when they are exposed to tumor-derived factors, as it 
happens in the tumor  environment. These findings  suggested that Osteoactivin may have a 
functional role in the important cross-talk between macrophages and cancer cells, and prompted us 
to investigate this hypothesis in vivo in murine tumor models.  
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Biological role of Osteoactivin   
 
Cell adhesion and migration: 
Some reports, in the scientific literature, show that Osteoactivin  is involved in important 
biological functions, such as cell adhesion, through its RGD domain and integrins, and also cell 
migration, in particular of with tumor cells [79, 80]. Therefore, we performed experiments to 
investigated if Osteoactivin could affect the adhesion and migratory properties of human 
monocytes and murine BM derived-monocytes.  
In vitro adhesion assays were performed using recombinant Osteoactivin  coated on plastic 
surfaces. Freshly isolated monocytes were plated onto the Osteoactivin layer and after 30 minutes 
of incubation the adherent cells were stained by Diff Quick kit and enumerated. We observed that 
Osteoactivin  greatly enhanced the adhesive of human monocytes (Fig 9 A).  
Moreover by a migration assay performed using transwell plates we observed that Osteoactivin  
could also function as a chemotactic factor inducing the migration of murine monocytes as 
efficiently as CCL2 that is considered a potent monocyte chemo-attractant (Fig 9 B).  
 
 
Fig 9. Monocyte adhesion and migration are enhanced by Osteoactivin .  A) Adhesion assay on OA-
coated wells. Human monocyte adhesion is enhanced by recombinant Osteoactivin  (+); data are shown as 
number of plastic adherent cells (OA 2ug/ml); Mean ± SE for 3 replicates. B) Migration assay. Murine 
monocyte migration is induced by Osteoactivin  (50 and 100 ng/ml), two experiments are shown (red and 
blue line). CCL2 (100 ng/ml) was used as reference chemo-attractant (green dot and square); data are shown 
as number of monocytes migrated through 5 μm pore size transwell filter. Statistical analysis: ∗p < 0.05,∗∗∗p < 
0.001 (Student’s t test). 
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Macrophage differentiation and polarization: 
In the scientific literature, Osteoactivin  is described as a key regulator of bone biology, 
especially during the differentiation of osteoblasts and osteoclasts [69]. Using recombinant 
Osteoactivin  as differentiation or polarization factor, we investigated the possibility that this 
protein could modulate monocyte-macrophage differentiation or M1/M2 macrophage polarization. 
To test this hypothesis we evaluated the expression of the typical markers of differentiated 
macrophages (CD68/F4-80) and M1/M2 macrophages (MHCII and CD206) on our monocytes 
stimulated with soluble Osteoactivin  during the culture period. Our results indicated that the 
recombinant protein had no significant effect on myeloid cell differentiation and neither on 
macrophage polarization (data not shown). 
Taken together the results indicate that Osteoactivin  is an interesting molecule expressed and 
released by tumor-conditioned macrophages both in humans and mice, involved in the stimulation 
of their migration and adhesion ability. 
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Mice of the DBA/2J strain lack functional Osteoactivin    
 
To investigate in vivo the functional role of the protein Osteoactivin  we took advantage of the 
mouse strain DBA/2J which displays a non-functional mutation in the Gpnmb gene.  The point 
mutation (GpnmbR150X ) introduces a premature stop codon with the consequent  formation of a 
truncated non-functional protein [70]. 
 
 
Fig 10.  Gpnmb gene mutation in DBA/2J strain. A) Sequence comparison of Gpnmb products 
amplified from wild type (WT) and DBA/2J (D2) tissues indicating the presence of a premature stop codon 
mutation: Gpnmb
R150X
; B) Representation of Osteoactivin  precursor protein and the predicted truncated  
protein encoded by Gpnmb
R150X 
[70]. 
 
 
The phenotype of Osteoactivin -defective mice (DBA/2J) does not show obvious major 
problems, with the exception of the known rapid onset of glaucoma. In fact, aging mice develop 
iris pigment dispersion (IPD) by sloughed off pigment cells, retinal ganglion cell loss and optic 
nerve head excavation[70]. Furthermore, the Jackson Company generated a transgenic mouse line 
reconstituted with the native functional protein: DBA/2J-Gpnmb
+
 mice. Therefore, both mice with 
non-functional Osteoactivin  and mice with the functional protein were available for this study. 
27 
 
Characterization of the monocyte/macrophage lineage in DBA/2J and 
DBA/2J Gpnmb
+
 
 
Before using the DBA/2J and DBA/2J Gpnmb
+
 mice in tumor models in vivo, we performed a 
general characterization of immune cells in these two strains, with a particular focus on the 
monocyte/macrophage lineage. Both the scientific literature and our results indicated that the two 
mouse strains had similar levels of circulating monocytes and spleen macrophages (not shown). 
To analyze general functions of macrophages from these mice, we generated in vitro 
differentiated macrophages from bone marrow-derived monocytes stimulated with M-CSF, and 
investigated the production of the principal macrophage products induced by different stimuli, 
including LPS and PamCys. Tab.1 shows the quantification of the principal cytokines produced by 
treated monocytes in DBA/2J or DBA/2J Gpnmb
+
 mice. With LPS stimulation, only monocytes 
from DBA/2J Gpnmb
+
 are able to produce chemokines such as KC, CCL3, CCL5 and eotaxin, and 
cytokines: IL-1b, IL-6, IL-10 and IL-12. Cells from DBA/2J mice are completely unresponsive to 
LPS. On the contrary both DBA/2J than DBA/2J Gpnmb
+
 monocytes are able to respond to 
PamCys  with the production of all the cytokines tested. Thus, our results highlighted a defective 
response of the DBA/2J strain to LPS.  
 
 
Tab 1. Cytokine production by in vitro monocytes from DBA/2J and DBA/2J Gpnmb
+
 
mice. When stimulated with LPS (24 hr), only monocytes from DBA/2J Gpnmb
+
 mice are able to produce 
high levels of chemokines and cytokines. Upon stimulation with PamCys,  monocytes  from both DBA/2J  
and DBA/2J Gpnmb
+
 mice respond equally well with higher production of the principal inflammatory 
mediators. Data are expressed in ng/ml. 
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As shown in Tab.2, also M1/M2 polarized macrophages from DBA/2J mice were unresponsive 
to LPS and did not produce any cytokine, with the exception of CCL2. Cytokine production was in 
general higher in M1/M2 macrophages derived from DBA/2J Gpnmb
+
 mice.  
 
 
Tab 2. Cytokine production by in vitro polarized macrophages from DBA/2J and DBA/2J 
Gpnmb
+
 mice. Only M1/M2 polarized macrophages taken from DBA/2J Gpnmb
+
 mice are responsive to 
LPS/IFNγ stimulation. Data are expressed in ng/ml.  
 
It would be very interesting  perform an accurate characterization of the monocyte/macrophage 
lineage in DBA/2J and DBA/2J Gpnmb
+
 to better understand differences in the inflammatory 
response of these cells, with particular attention to the LPS –TLR pathway. In the literature, in fact, 
there are contrasting results on the expression of TLR in these strains and  their response to LPS 
[81, 82].  
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Osteoactivin  in the tumoral context 
 
To understand the role of Osteoactivin  in the tumoral context we tested different in vivo tumor 
models taking advantage of the availability of the two different mouse strains. 
We first tested the P815 cell line, a murine mastocytoma syngeneic for the DBA/2J strain. P815 
cells (10
6
 cells) were injected intraperitoneally (i.p.) in DBA2J and in DBA/2J Gpnmb
+
 mice. We 
observed that in both groups animals developed a similar amount of ascites and similar tumor load 
(Fig 11A) These tumors did not present differences also in the tumor microenviroment composition 
as observed by FACS analysis (Fig 11B). 
 
 
Fig 11. P815 trasplantable tumor model. A) Amount of intraperitoneal ascites at 14° day after tumor 
cell injection; the total volume is similar in DBA/2J and DBA/2J Gpnmb
+
 mice. Data are shown as volume 
(ml) as means ± SE); B) Percentage of cell content into tumor ascites. The amount of tumor cells and 
macrophages is similar into both mouse strains. Data are shown as % of cells compared to total CD45 
positive cells (Mean means ± SE). 
 
The low availability of murine tumor models syngeneic for this particular strain prompted us to 
develop a carcinogenesis model upon treatment with the carcinogen methylcholanthrene (MCA). A 
subcutaneous injection of 500ug 3MCA was given to DBA/2J and DBA/2J Gpnmb
+
 mice. Mice 
were constantly monitored for four months for the generation of MCA-induced fibrosarcoma. The 
two groups developed primary tumors starting from 16 weeks after MCA injection; no significant 
differences were observed in terms of tumor incidence and mean size of the tumors was 
comparable (data not shown).  
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Although we did not observe any particular difference in the two groups, this experiment has 
been useful to establish in vitro cells from the primary tumors: we expanded and established as 
proliferating cell lines two tumors originated from DBA/2J mice (G2 and G3 cell lines) and two 
from DBA/2J Gpnmb+  mice (G4 and G5 cell lines).  
To confirm that the cell lines were indeed stable and to assess their capability to re-grow in vivo 
we performed a transplantation experiment with two of the four selected fibrosarcoma cell lines: 
G2 cells (from DBA/2J) and G4 cells (from DBA/2J Gpnmb+). Tumor cells (5x10
5
) were 
intramuscularly injected in each respective syngeneic mouse. All mice developed tumors within 15 
days as shown in Fig 12 A-B. 
 
 
Fig 12. G2 and G4 Transplantable tumor model. A and B) Tumor growth curves of G2 cells (DBA/2J) 
and G4 cells (DBA/2J Gpnmb
+
 ) into their syngeneic mice, respectively; in the two graphs each line 
represent an individual tumor. C) Mean values of tumor volume of G2 and G4 tumors (10 mice per group). 
Data are expressed in mm
3
 of volume determined by external caliper. Statistical analysis: ∗∗∗p < 0.001 
(Student’s t test). 
 
 
Although tumor growth in mice was highly heterogenous, likely because this was the first 
transplantation experiment with these primary fibrosarcoma, it was apparent that the two tumor cell 
lines had a different rate of proliferation.  G2 tumors were growing more rapidly compared to G4 
tumors and formed larger masses (Fig. 12 C).  G2 tumors originate from DBA2/J mice with non-
functional Osteoactivin , while G4 tumors were generated in DBA/2J Gpnmb
+
 mice, which are able 
to produce a functional protein. Nevertheless, no hypothesis are worth mentioning at this stage on a 
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possible impact of Osteoactivin  on the in vivo tumor growth, as this difference could be ascribed to 
intrinsic properties of the originally transformed cells. 
In order to understand whether Osteoactivin  is a pro-tumoral or antitumoral protein, we injected 
G2 tumor cells (Osteoactivin-defective) in DBA/2J Gpnmb
+
 mice (Osteoactivin competent) and in 
in DBA2J  mice for comparison.  To better appreciate possible differences in tumor incidence and 
growth rate, we reduced the number of injected tumor cells (5x10
4
). We injected cells 
intramuscularly and monitored mice over time for tumor development. Six weeks later, the 
incidence of tumor take was 38.5%  in DBA/2J and 50% in DBA/2J Gpnmb
+
 mice. Some of the 
tumors in DBA/2J Gpnmb
+
 mice proliferated remarkably faster forming very large masses and 
disseminated to the lungs.  
 
 
Fig 13. G2 trasplantable tumor model in DBA/2J and DBA/2J Gpnmb
+
 mice. A and B) Tumor 
growth curve after injection of 5x10
4
 G2 (OA neg) cells into DBA/2J and DBA/2J Gpnmb
+
 mice. Data are 
expressed in mm
3
 of volume determined by external caliper. Upon an initial similar growth rate, after 6 
weeks tumors grew more rapidly in DBA/2J Gpnmb
+
 . C) Tumor incidence expressed as percentage of 
mice developing tumors. E) Number of lung metastasis. Each dot represents an individual mouse.  
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These results clearly indicated that Osteoactivin  expression in the stromal microenvironment, 
perhaps by macrophages, may provide a proliferative advantage to tumor cells which acquire a 
more aggressive phenotype in vivo. 
Considering the observed effect of Osteoactivin  in the tumor microenvironment and given that 
its expression is increased in several types of cancer, we decided to directly engineer MCA-OA
– 
cells to express the native protein and obtain isogenic cell lines expressing or not Osteoactivin.  
We cloned the murine gpnmb gene and expressed it in a lentiviral pRRL Sin plasmid in which 
egfp has been replaced with mCherry (Fig 14A); we transduced two different MCA-OA
-
 cell lines 
(G2 and G3). mCherry-positive cells were selected by FACS sorting, propagated and checked for 
OA expression on cell membrane and for the secreted form. Both G2 and G3 cell lines were 
successfully transduced. As G2 cells showed better results, we decided to use this cell line in future 
experiments. Fig 14 shows that the G2 trasduced with Osteoactivin  cells, called G2 OA, highly 
expressed both the transmembrane form (Fig 14B) and the secreted protein (Fig 14C). Fig 14D 
shows by confocal microscopy the expression of the cherry-linked transgene: the protein 
Osteoactivin  is mainly localized on the cell membrane, while in MOCK-transduced cells (G2 
MOCK) the mCherry dye is mainly intra-cytoplasmic.    
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Fig 14. Characterization of OA-transduced G2 cell line. A) Scheme map of the lentiviral plasmid; B) 
FACS profile plot of transmembrane Osteoactivin  in G2 OA (black line) and G2 MOCK-transduced cells 
(grey profile); C) Quantification of soluble isoform of Osteoactivin  in G2 OA and G2 MOCK-transduced 
cells; D) Confocal images of Osteoactivin  in G2 OA and G2 MOCK transduced cells (OA in red - DAPI in 
blu).  
 
 
G2 OA and G2 MOCK cell lines were initially characterized in vitro. Both cell types had a 
stable and similar rate of proliferation as evidenced in growth curve experiment within the short 
period of 72 hrs (not shown). The next step was to evaluate if the presence/absence of Osteoactivin  
within tumor cells could affect tumor growth in vivo in mice. To this purpose we inoculated G2 OA 
and G2 MOCK cells in vivo.  
We first used NOD/scid IL2Rg
null
 (NSG) immunodeficient mice, to avoid the possibility that the 
OA protein could be recognized as “foreign” by DBA/2J immunocompetent mice. Tumor cells 
(10
5
) were intra-muscularly injected and tumor growth followed over time.  Surprisingly, tumors 
from G2 OA
 
cells were already palpable after 10 days, while tumors from G2 MOCK cells 
appeared around day 15-20 (Fig 15A). Osteoactivin-transduced tumors grew more rapidly than 
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MOCK cells and tumor weight was significantly higher at sacrifice (Fig 15B). Furthermore G2 OA 
tumors disseminated to the lungs and formed more metastasis compared with MOCK tumors (Fig 
15C).  These results in NSG mice indicated that tumor cells producing Osteoactivin  had features of 
more aggressive tumors as far as proliferation rate in vivo and spreading to distant organs.     
 
 
 
Fig15. G2 OA/ G2 MOCK transplantable tumor model in NSG mice. A) Tumor growth curve after 
inoculation of 10
5
 G2 OA or G2 MOCK cells into NSG mice. Data are expressed in mm
3
 of volume 
determined in vivo by external calliper. B) Tumor weight of tumors. C) Number of formed lung metastasis. 
Each dot represents an individual mouse. Results are from one representative experiment of three performed 
with similar results. Statistical analysis: ∗p < 0.05, ∗∗∗p < 0.001 (Student’s t test). 
 
 
We next investigated by immunoistochemistry (IHC) the presence of macrophages and blood 
vessels, in order to study the composition of the tumor microenviroment. Surprisingly G2 OA 
tumors had significantly lower levels of F4/80
+
 macrophages and CD31
+
 vessels compared to 
MOCK tumors (Fig 16). The finding that more aggressive tumors (G2 OA) contained fewer 
macrophages, compared to their counterpart,  was unexpected, especially because our previous 
experience with MCA-induced tumors evidenced that the microenviroment is highly populated by 
TAM,  and their presence is usually associated with pro-tumoral functions [83]. To go more in 
depth in the characterization of the microenviroment composition of OA-transduced tumors, we 
evaluated also the presence of activated fibrobasts and collagen deposition by IHC.  We observed 
that G2 OA tumors were richer in collagen content and density of SMA
+
 activated fibroblasts 
compared to MOCK tumors as shown in Fig 16. 
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Fig 16. Immunoistochemistry analysis of G2 OA and G2 MOCK tumors from NSG mice. A) 
Representative IHC images of tumor sections stained for F4/80, CD31, SMA and Collagen (Sirius red) at  
original magnification 20X. B) Immunoistochemistry analysis. Results are calculated as mean of five 
microscope fields for each sample. Images were analyzed using Image-ProAnalyzer software. The positive 
area for macrophages (F4/80
+
) and the number of vessels (CD31
+
) are higher in G2 MOCK tumors comapred 
to G2 OA. On the contrary, the numbers of activated fibroblasts (SMA
+
) and collagen content (Sirius red
+
) 
are higher in G2 OA tumors. Statistical analysis: ∗p < 0.05, ∗∗∗p < 0.001 (Student’s t test). 
 
 
To reinforce the above results of lower amount of TAM and vessels and higher density of 
activated fibroblasts, we performed real-time PCR on samples collected from G2 OA and G2 
MOCK tumors from NSG mice to quantify mRNA levels of the principal macrophages markers, 
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such as CD68 or CD163, chemotactic factors CCL2 or VEGF,  fibroblastic factors, such as EGF 
and FGF, and MMP2 a protease involved in ECM degradation. As shown in Fig17 it was 
confirmed that CD68 and CD163 levels were lower in G2 OA tumors compared to MOCK ones 
(Fig 17A). RNA levels of CCL2, a major chemotactic factor for macrophages, were also decreased, 
at least partially explaining the lower density of TAM in these tumors (Fig17A).  On the other 
hand, RNA levels of MMP2, EGF and FGF were increased in G2 OA tumor samples, and the 
results are in line with the higher amount of activated fibroblasts observed by 
immunohistochemistry (Fig 17B). 
 
 
Fig 17. mRNA levels in G2 OA and G2 MOCK tumor samples. (A) Expression levels of macrophage 
markers CD68 and Cd163, CCL2 and VEGF in tumors of NSG mice. (B) Expression levels of 
metalloprotease-2 and fibroblasts-related growth factors. Statistical analysis: ∗p < 0.05, ∗∗∗p < 0.001 
(Student’s t test). 
 
 
To evaluate whether the tumor cell line expressing Osteoactivin  could be able to grow faster 
also in immunocompetent mice, we next performed the same type of experiment using the 
syngeneic DBA2/J mice.  G2 OA and G2 MOCK cells were intramuscularly inoculated (10
5
). 
Tumors grew slowly and for the first three weeks both types of tumors had the same proliferation 
rate (Fig 18A). However, after 3 weeks the volume of G2 OA tumors was larger, as well as tumor 
weight at sacrifice (Fig 18B); G2 OA tumors disseminated to lungs in some mice, while G2 MOCK 
tumors never formed metastasis (Fig 18C). 
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Fig 18. G2 OA/G2 MOCK transplantable tumor model in DBA/2J mice. A) Tumor growth curve 
after inoculation of 10
5
 G2 OA or G2 MOCK cells into DBA/2J mice. Data are expressed in mm
3
 of volume 
determined in vivo by external caliper; B) Tumor weight at sacrifice. C) Number of lung metastasis, each dot 
represents an individual mouse. G2 OA tumors have higher proliferation rate and formed more metastases 
than G2 MOCK tumors. Graphs are a representation of two independent experiments, with similar results. 
Statistical analysis: ∗p < 0.05, ∗∗p < 0.01, (Student’s t test). 
 
 
The immunohistochemistry of tumor sections again revealed that OA-expressing tumors 
contained lower amounts of macrophages and vessels, and higher density of activated fibroblasts 
(Fig 19). Collagen staining did  not reveal any differences in the two groups (data not shown), this 
is probably due to the fewer amount of activated fibroblasts in these tumors compared to tumors 
derived from NSG mice. Similarly to what we observed in NSG mice by real-time PCR, we found 
that G2 OA tumors had lower amount of CD163 and CCL2, but not of CD68 or VEGF. Moreover 
MMP2 is much more expressed in G2 OA tumors, compared to G2 MOCK cells, while there is 
only a slight increase of EGF and FGF (Fig. 20). Overall, these results in syngeneic 
immunocompetent mice are in line with the immunohistochemistry analysis previously performed 
in immune-deficient NSG mice (shown in Fig 16). 
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Fig 19. Immunoistochemistry analysis of tumors taken from DBA/2J mice. A) Representative IHC 
images of tumor sections stained for F4/80, CD31, and αSMA at original magnification 20X. B) 
Immunoistochemistry analysis. Results are calculated as mean of five microscope fields for each sample. 
Images were analyzed using Image-ProAnalyzer software. The positive area for macrophages (F4/80
+
) and 
the number of vessels (CD31
+
) are higher in G2 MOCK tumors compared to G2 OA. On the contrary the 
number of activated fibroblasts (SMA
+
) is higher in G2 OA tumors. Statistical analysis: ∗p < 0.05, ∗∗∗p < 
0.001 (Student’s t test). 
 
 
 
 
Fig 20. mRNA levels in DBA/2J tumor samples. (A) Expression levels of macrophage markers CD68 
and Cd163, CCL2 and VEGF  and (B) of MMP2, FGF, EGF in tumors from DBA/2J mice. Statistical 
analysis: ∗∗p < 0.01, (Student’s t test). 
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So far the results demonstrated that tumor cells producing Osteoactivin  grew differently in vivo  
compared to non-expressing cells, in  both immune-deficient and immune-competent mice, 
showing a higher proliferation rate and metastatic behaviour.  
 We therefore started to suspect that Osteoactivin-producing tumors contain a higher 
proportion of tumor-initiating cells. To test this hypothesis, we performed an in vivo experiment 
inoculating a very low number of tumor cells. As low as 10
3
 G2 OA and G2 MOCK cells were 
injected in NOD/scid IL2Rg
null
 (NSG) mice testing their tumorigenicity. Surprisingly, as shown in 
Fig.21, G2 OA tumors were already detectable starting from the 15
th
 day post-injection, much 
earlier than the MOCK counterpart. 
 
 
Fig 21. Tumorigenicity of G2 OA and G2 MOCK tumors in NSG mice. A) Tumor growth curve after 
inoculation of 10
3 
G2 OA or G2 MOCK cells in NSG mice. G2 OA
 
 tumors grow much more rapidly than G2 
MOCK ones. B) Tumor volume expressed in mm
3
 of volume determined in vivo by external caliper. 
Statistical analysis: ∗∗∗p < 0.001 (Student’s t test). 
 
 
 
The results indicate that Osteoactivin provide tumor cells with a proliferative advantage so that 
even a small number of cells could rapidly develop and form tumors in vivo. Overall these findings 
are in line with those observed in the previous experiments, where OA-negative tumor cells grew 
faster and more aggressively in DBA/2J Gpnmb+ mice; in these mice, Osteoactivin can be produced 
by the stromal compartment, including macrophages. Therefore we conclude that either when 
endogenously produced, or when secreted in the tumor milieu, this protein has pro-tumor functions 
and facilitates tumor development.  
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In vitro characterization of engineered cell lines 
 
Starting from the observation of the different pattern of in vivo growth and higher 
tumorigenicity of G2 OA cells,  we further characterized in vitro the proliferation rate of our 
engineered cell lines, in a longer assay than previously performed, and their ability to survive under 
non-optimal conditions. After plating, cells were counted every 24h without change of medium. 
Until 72 hours we did not observe any differences in term of growth; in contrast, after 4 days 
MOCK cells started to die, while Osteoactivin-expressing cells continued to grow actively (Fig 22 
A). These data indicate that under conditions of nutrient/serum deprivation, G2 MOCK cells 
progressively die, while  G2 OA cells are able to survive.  Furthermore,  after a period of 96 hours, 
G2 OA cells gradually detached from plastic surface and were able to proliferate in an anchorage-
independent manner, giving rise to  spheroids (Fig 22 B).  
 
 
Fig 22. In vitro growth of G2 OA and G2 MOCK cells. A) growth curve of  G2 OA and G2 
MOCK cells; G2 OA cells (red line) grow with a more rapid rate compared to G2 MOCK 
counterpart (black line); Data are expressed as population doubling (PD) that represents the number 
of cell duplications. The growth curve started from 2x10
5
 cells. Statistical analysis: ∗∗p < 0.01, 
(Student’s t test). B) Representative picture of spheroids formed by G2 OA cells  after one week of culture. 
On the left side the monolayer formed by G2 MOCK cells. 
 
Considering that the ability to form sphere is a typical feature of stem cells, we decided to 
switch the usual culture medium (RPMI1640) with the Iscove medium without FBS and 
supplemented with specific factors: mEGF, mFGF, B27 and N2. Under these conditions, we 
observed that all G2 OA cells were able to form spheres, while only 30% of G2 MOCK cells did 
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so. In order to check their self-renewing ability, spheres of G2 OA and G2 MOCK cells were 
harvested, trypsinized to have single cell suspension and re-plated in culture; a second round of 
subsphere-forming assay was performed. Only G2 OA cells were able to form secondary and 
tertiary spheres while MOCK cells did not have this self-renew ability (Fig 23).  
 
 
Fig 23. Sphere-forming assay. G2 OA cells were able to form spheres, while only 30% of G2 
MOCK cells did so (upper part of the picture). G2 OA cells are able to form secondary and tertiary 
spheres starting from a single cell suspension of their primary/secondary spheres. In the lower part 
of the figure representative pictures taken after a week of culture with light and fluorescence 
microscopy at magnification 20X that show primary, secondary and tertiary spheres formed by 
G2OA cells. 
 
 
 
This self-renewal property prompted us to investigate in depth the expression of markers typical 
of tumor stem cells. Cancer stem cells do not have a unique set of markers because their expression 
depend on the nature of formed tumors. The pathological analysis on our tumor samples revealed 
that G2 MOCK and G2 OA cells form mesenchymal tumors. To test whether the sphere forming 
cells could be really cancer stem cells as we assumed, we studied the expression of typical 
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mesenchymal stem cell markers, such as CD44, Sca1, CD117 (c-Kit), CD135; we also tested 
typical hematopoietic stem cell markers (CD45, CD11b, F4/80 and CD34) and a generic stem cell 
marker: Sox2. We evaluated the expression of these markers in G2 MOCK, G2 OA adherent cells 
and G2 OA spheres. All the cells analyzed did not express hematopoietic markers, with the only 
exception of CD34; this protein was expressed in all the adherent cells, but decreased when they 
become spheres. Both G2 MOCK and G2 OA cells expressed CD44, but not CD135, both in 
adherent cells and in cells in suspension. Sca1 was expressed only in G2 OA cells (adherent or 
spheres), while in MOCK cells was present at very low levels. Two typical markers expressed by 
our spheres were  CD117 and Sox2, their levels increased in secondary formed spheres (Fig. 24).  
 
 
 
 Tab 3. Expression of cancer stem cell markers. Cytofluorimetric staining panel of G2 OA and G2 MOCK 
cells grown in Iscove medium (without FBS) supplemented with  mEGF, mFGF, B27 and N2; Primary and 
secondary G2 OA spheres express high level of  CD117, Sca1 and Sox2 and they are negative for the most 
part of the other markers we tested.  
 
 
 
 
Fig 24. Representative profile of Sox2 expression.  Primary and secondary G2 OA spheres 
express high levels Sox2.  
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We also evaluated the mRNA levels of the principal transcriptional factors typical of cancer 
stem cells; not surprisingly, we found that NANOG, OCT 3/4, DNMT and Brachyury were higher 
in G2 OA cells compared to G2 MOCK cells. In particular,  their expression increased when G2 
OA cells grew as spheroids,  in fact mRNA levels resulted significantly higher in primary spheres  
as well as in secondary ones (Fig 28/25). 
 
 
Fig 25. mRNA levels of stemness-related transcriptional factors.  G2 OA cells (blue bars) express 
higher levels of  OCT3/4, DNMT and Brachyury compared to G2 MOCK cells (white bars). The expression 
of these genes and the expression of NANOG increase when G2 OA cells grew as spheroids (green bars) and, 
in many cases, also in secondary spheres. Statistical analysis: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (Student’s t 
test). All samples are tested in triplicate; Mean values ± SEM. 
 
 
Taking advantage of the availability of in vivo-grown tumor samples from the above 
experiments, we performed other real-time PCR analyses to detect the typical transcription factors 
of stemness. We observed that NANOG, OCT 3/4, SOX2 and Brachyury were indeed 
overexpressed in G2 OA tumors compared to G2 MOCK tumors, with particular significant 
differences in samples grown in NSG mice (Fig 29). 
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Fig 29. mRNA levels of stemness-related transcriptional factors. Principal transcriptional factors 
involved in cell stemness in G2 OA
 
and G2 MOCK tumor samples in both NSG (A) and DBA/2J (B) mice (5 
mice/group). The higher expression of NANOG, OCT 3/4, SOX2 and Brachyury by G2 OA tumors 
compared to G2 MOCK tumors is significantly different. Statistical analysis: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 
0.001 (Student’s t test). In tumors of NGS mice, only NANOG and Brachyury are increased. Data are 
expressed as fold increase compared to G2 MOCK cells. All samples are tested in triplicates. Mean values ± 
SEM.  
 
Collectively, our data demonstrate that the exogenous expression of Osteoactivin  by tumor 
cells is associated with features of stemness.  The up-regulation of typical stem cell markers, in 
Osteoactivin-producing cells, is likely related to their enhanced survival and proliferation ability, 
and higher tumorigenicity in vivo. These data bring us to speculate that also the Osteoactivin  
produced by tumor-associated macrophages might support cancer stem cells and enhance survival 
and proliferation of tumor cells.  
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DISCUSSION 
 
 
Tumor-associated macrophages (TAM) represent a major leukocyte component of solid tumors 
and it is now established that they are key players in the buildup of the inflammatory 
microenvironment. TAM perform mostly pro-tumoral function supporting angiogenesis, tumor 
growth and metastatization  processes and suppression of adaptive immune response.  Pre-clinical 
and clinical evidence firmly demonstrated a correlation between high TAM density within tumor 
mass and poor patient prognosis for the majority of tumors [22-25]. 
 In our study, from the analysis of a gene expression profiling of macrophages co-
cultured with tumor cells (tumor-conditioned macrophages), we found that these cells are able to 
express and release a factor: GPNMB/Osteoactivin, which may be involved in the cross-talk 
between cancer cells and macrophages [59] .  
In the scientific literature, Osteoactivin  is presented as a protein expressed by several cell types 
and possibly involved in many physiological and pathological conditions. However, results on the 
functional activities of Osteoactivin  are frequently conflicting. In normal tissues Osteoactivin  has 
been described as “controller” of cell differentiation and cell adhesion especially in fibroblasts, 
epithelia and bone cells [69]. Some studies have described an immuno-regulatory function of this 
protein, either as inhibition of T cell activation [15], or in contrast, as stimulator of dendritic cell 
mobilization and defensive function against pathogens [84]. In the mononuclear phagocyte system 
Osteoactivin  has been found expressed in the microglia of brain, where it exerts protective 
functions for neurons and  in osteoclasts, where it participates in the maintenance of bone 
homeostasis.   
In pathological conditions of tissue damage (kidney, liver, muscle) this protein is always 
upregulated and its presence is regarded as important for the healing tissue, probably via the 
scavenging of debris and activation of MMPs in the remodeling phase [75, 77]. Its absence in 
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experimental models is always associated with delay of  tissue repair. In tumors, OA expression 
has been described in melanomas, gliomas and breast cancer.  
Despite its original name (glycoprotein non-metastatic B) due to its first definition in low 
metastatic melanomas,  it is now clear that Osteoactivin  is expressed by highly malignant 
melanomas as well as in other tumors, and its expression  has been linked with increased tumor 
growth, invasiveness and metastasis, especially in breast cancer, but opposite results have been 
described in prostate carcinomas [73, 85-87]. In recent years, attempts to target  Osteoactivin  
therapeutically have been pursued: a clinically available anti-Osteoactivin  antibody conjugated 
with the cytotoxin auristatin E has been developed and is currently under investigation in oncology 
trials in patients with melanoma and breast cancer [88].  
Knowledge on the mechanism of action of this molecule is also  insufficient. The 
transmembrane  isoform  contains a hemi-ITAM motif with a theoretical signaling capacity, though 
not formally demonstrated. The secreted form has been reported to bind to the receptor CD44 via 
ERK/AKT signaling [89]. The most consistent results in the literature define that this molecule 
favors cell-cell adhesion and cell mobilization, via RGD-integrin binding; these are important 
processes involved in several physiological and pathological conditions. An important determinant 
of the functional activity of this protein appears to be its state of glycosylation in the extra-cellular 
PKD domain, which adds a further level of complexity in the interpretation of the results obtained 
with the native and the recombinant produced protein. 
 In our study we found that Osteoactivin  is induced upon M-CSF- driven macrophage 
differention and it is upregulated by anti-inflammatory stimuli. Instead, a study by Ripoll et al 
(2007) reported that Osteoactivin  is induced in macrophages by LPS and IFNγ, a finding that we 
did not confirm, as our results clearly showed a down-regulation of this molecule by inflammatory 
stimuli. As a matter of fact, its expression in TAM, its upregulation by tumor supernatants and by 
IL-10, and its expression in resolving macrophages, more likely calls for a regulatory and tissue 
protective role for this protein [75]. 
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Aim of our study was to identify the biological significance of Osteoactivin expression in 
macrophages conditioned by the tumor microenvironment.  
The availability of commercial mouse strains with functional or non-functional protein: DBA/2J 
(OA-) and DBA/2J Gpnmb
+
 (OA
+
) mice was a real advantage for our experimental in vivo studies. 
As described above, the phenotype of Osteoactivin-defective mice (DBA/2J) does not show evident 
major problems, with the exception of the known rapid onset of glaucoma, but less is known about 
their immunological status. In this study we observed that monocytes and macrophages from 
DBA/2J mice are less responsive to LPS stimulation. In the literature, there are contrasting results 
on the expression and signaling functionality of the TLR4 receptor in DBA/2J mice. One study 
investigated the transcriptional program of macrophages from different mouse strains in 
response to LPS; the authors reported that, in spite of great variation in the number of modulated 
genes,  DBA/2J mice had a similar profile compared to C57Bl6 mice [90]. Another study showed 
that BXD29 mice, which have a DBA/2J background, have a mutated TLR4 and attenuated 
response to LPS [81]. Thus, in addition to the well characterized C3H/HeJ strain with mutated 
TLR4, also DBA/2J mice may not optimally respond to bacteria.  As far as susceptibility to 
pathogens, DBA/2J mice appear to be more susceptible than C57BL/6J mice to Streptococcus 
Group A infection, a Gram positive bacterium  and also to viral infections such as several influenza 
virus subtypes. [91] [92] 
The main reason to use DBA/2J mice in our study was the reported absence of a functional 
Osteoactivin protein in this strain. Using both the defective strain and the reconstituted DBA/2J 
Gpnmb
+
  mice, we explored whether tumors were developing with a different growth rate. We first 
investigated  a syngeneic transplantable tumor model: the P815 murine mastocytoma cell line, and 
found no significant differences in terms of tumor take and volume in the two mouse strains.  In 
those experiments we injected a high number of cells (10*6) and this may have masked a small but 
important difference in tumor growth. In fact, with the fibrosarcoma model, we appreciated an 
accelerated tumor growth in DBA/2J Gpnmb
+
  mice only when using a small number of injected 
tumor cells.  We plan in the future to perform another experiment  with a lower number of P815 
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cells to verify if also in this model we can appreciate more tumor rapid growth in Osteoactivin-
competent mice.  
As DBA/2J syngeneic tumor models are very few, we decided to generate primary tumors in the 
two mouse strains by chemical carcinogenesis. This was also informative regarding the incidence 
of neoplastic transformation, which was, however, similar in OA-proficient and deficient mice. 
Some of the chemically-induced fibrosarcoma that developed after some months were re-
transplanted to generate tumor cell lines stably growing in vivo. In particular, an informative 
experiment was to inject a fibrosarcoma generated in DBA2/J OA-deficient mice, in OA-proficient 
animals.  We observed higher tumor take and faster tumor proliferation compared to tumors grown 
in DBA/2J mice. These results suggested that Osteoactivin  expression in the tumor micro-
environment by macrophages or stromal cells of DBA/2J Gpnmb
+
 mice might be able to support 
tumor growth.  
To directly investigate the biological effect of Osteactivin on tumor development, we 
engineered OA
-
 tumor cells to express the native protein, with the aim to verify if OA-expressing 
cancer cells had a different growth pattern in vivo. This was indeed the case, with remarkably 
earlier and faster tumor growth in vivo and higher metastatic capacity compared to MOCK-
transduced cells.  These results were consistent both in the syngeneic strain and in immunodeficient 
NSG mice.  The finding that Osteoactivin expression correlated with more aggressive tumor 
behavior is in line with literature data  as reported by  Rose et al [73, 93]. 
An unexpected finding in our studies was the fact that tumors formed by OA-transduced cancer 
cells contained significantly lower numbers of macrophages. Our group has quite a good 
experience in the characterization of macrophages infiltrating chemically-induced fibrosarcoma. 
These tumors are usually rich in TAM, which are recruited at tumor sites primarily by the 
chemokine CCL2, produced by macrophages themselves and to a lower extent by tumor cells. Our 
group previously reported that TAM have essential trophic functions for fibrosarcoma cells, and 
their pharmacological depletion or inhibition of recruitment, significantly impair tumor growth. 
Furthermore, macrophages in tumors strongly correlate with higher metastatic ability [94, 95]. 
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Based on our previous experience, it was therefore surprising to find fewer TAM in Osteoactivin-
transduced tumors which grew faster, formed larger masses and were metastatic. When we 
explored the expression of CCL2 in tumors, this chemokine was significantly less produced, which 
may explain the low presence of macrophages. Although we cannot exclude that Osteoactivin 
directly inhibits the expression of CCL2, the most likely explanation is that the few macrophages 
inside OA-transduced tumors produce too little CCL2 to amplify the recruitment of blood 
circulating monocytes. The question, then, is why tumor cells have such a high proliferative rate 
even in the absence of the trophic effect of macrophages. Our subsequent results, as discussed 
below, point to an effect of Osteoactivin directly on cancer cells. 
Other differences were apparent in the micro-environment of OA-transduced tumors. We 
observed a reduced number of blood vessels, which is also counter-intuitive in large tumor 
volumes, and lower levels of the vascular growth factor VEGF. Instead, a greater number of 
activated fibroblasts and increased collagen deposition were found compared to MOCK-transduced 
tumors. More collagen deposition is likely the result of more active fibroblasts which might be 
stimulated by the increased expression of FGF in these tumors. These results may be related to the 
described ability of Osteoactivin in promoting tissue healing in experimental models of tissue 
injury [75]. Along this line, also MMPs, such as MMP2, were increased in OA-positive tumors. In 
the literature, MMP2 expression has been regarded as a major determinant of the metastatic ability 
of Osteoactivin positive tumors [93]. Finally, we preliminarily investigated the infiltration of CD3+ 
lymphocytes in OA-transduced tumors and, although no definitive conclusions can be made, there 
were no substantial differences (not shown). 
An important observation that shed light on the biological function of Osteoactivin in tumors 
was the different behavior of  OA+ tumor cells and MOCK-cells in vitro.   We found that when 
cultured in vitro in sub-optimal conditions (low nutrients, serum-free), OA+ tumor cells were able 
to survive for several days, while MOCK-cells rapidly died. OA-expressing cells progressively 
detached from plastic and formed large spheroids, growing in an anchoring-independent manner. 
These features are reminiscent of those displayed by cancer stem cells (CSC). 
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The existence of CSC or tumor-initiating cells has been confirmed in a variety of tumors, 
including breast, lung, colon, pancreatic and prostate cancer, as well as in melanoma, glioblastoma, 
hepatocellular carcinoma, and acute myeloid leukaemia [96-98]. CSC rest in a peculiar cellular 
niche within the tumor mass where they are protected from immuno-surveillance, apoptosis and 
chemotherapeutic drugs; the niche provides key signals that sustain, drive and promote their 
stemness [99, 100].  
The connection between macrophages in tumors and CSC has been studied only in recent years  
[101]. It has been reported that TAM and CSC are subject to an intense cross-talk in which the 
production of TGFβ or growth factors (EGF) by TAM, supports CSC survival and protect them 
against external apoptotic signals;  CSC, in turn,  attract and reeducate macrophages through the 
secretion of chemoattractants, among which CCL2, CCL5 and VEGF-A, to eventually support 
tumor growth. TAM number and disposition in tumor niche seem to be correlated with number and 
disposition of CSC [102-105].  
To confirm the hypothesis that OA-producing tumor cells might contain a higher proportion of 
CSC, we propagated spheroids in culture and observed that only OA-cells were able to form 
secondary and tertiary spheres, while MOCK cells did not have this self-renew ability.                 
We next investigated the expression of various stem cell markers in our fibrosarcoma cells grown 
as spheroid and, indeed, the expression of Sox2, NANOG, OCT 3/4 and Brachyury was higher in  
OA-tumor cells forming spheres, compared to MOCK-tumors not producing Osteoactivin. Notably, 
the enrichment of stem cell markers was also confirmed in tumors samples grown in vivo from OA-
tumor cells.  
Furthermore, as an important feature of CSC is to be tumorigenic,  we performed an in vivo 
experiment by injecting in mice only 1000 cells, a very low cell number. Osteoactivin-transduced 
fibrosarcoma cells were able to form tumors in just 15 days.  Although also MOCK cells were 
tumorigenic, tumors were palpable much later, after 30 days. 
 Collectively, these results indicate that Osteoactivin  has an important effect in promoting the 
survival, proliferation and stemness of tumor cells. 
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These findings open new questions that we need to address in the near future. An important issue is 
to reproduce these results with other tumor cell lines. We will first test another  Osteoactivin-
transduced  fibrosarcoma (G3OA and G3Mock) and inject them in NSG mice to verify and obtain 
confirmation that OA-expressing tumor cells grow more rapidly in vivo. Furthermore, we have 
already screened several other tumor cell lines for their spontaneous ability to produce and secrete 
Osteoactivin; we will evaluate in vitro if Osteoactivin-producing cancer cells preferentially form 
spheres in culture and acquire  a stem cell phenotype. As a complementary experiment, we will 
silence the production of  Osteoactivin  in OA-producing tumor cells and evaluate if tumor take and 
growth is decreased.   
An important question is the role of macrophages that, we know, produce Osteoactivin when co-
cultured with tumor cells. Is the macrophage-derived Osteoactivin able to sustain tumor 
proliferation and stemness? To explore this question we will perform  co-culture experiments of 
macrophages and Osteoactivin-defective tumor cell lines to evaluate whether Osteoactivin  
produced by macrophages is able to up-regulate stem cell markers and induce sphere-forming 
ability in tumor cells.   
Furthermore, to unequivocally identify the nature of the Osteoactivin-producing cells in the tumor 
micro-environment, we will perform a bone marrow transplant experiment (BM from DBA/2J 
Gpnmb
+
 mice into DBA/2J mice). This experiment will allow  us to demonstrate if hematopoietic 
cells (monocytes) recruited at tumor sites are the source of Osteoactivin, or instead, other stromal   
cells such as fibroblasts are the producer cells. 
In conclusion, we have provided  initial demonstration that a factor produced by macrophages in 
the tumor context facilitates the amplification of cells with CSC features, thus favoring tumor 
proliferation and dissemination and likely resistance to therapeutic strategies. This new pathway of 
Osteoactivin-mediated macrophage-cancer cell cross-talk adds on the already long list of pro-
tumoral activities of TAM.  
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MATHERIALS AND METHODS 
 
Cell biology 
 
Cell culture  
Human PT45 and PANC1 tumor cell lines, murine P815, MN-MCA1, PANC02, G2, G3, G4, 
G5, G2 OA and G2 MOCK tumor cell lines were cultured in RPMI1640 (Lonza) supplemented 
with 10% FBS (Sigma), 2mM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin (all 
from Life Technologies Inc.) and in tissue culture flasks (Corning, Stone Staffordshire, UK) at 37 
°C and 5% CO2.  
In order to obtain spheroids from G2 OA and G2 MOCK cells we cultured them in Iscove 
medium (with 1%FBS or without FBS) and  supplemented with specific factors: mEGF, mFGF 
(PeproTech), B27 and N2.  
 
Cell stimulation and Tumor-Conditioned Media Preparation 
Monocytes were stimulated with Glucocorticoids (MP Biomedicals) used 100uM; hM-CSF, 
GM-CSF, TGF , IL-10, IL-1, IL-13, IL-4, TNF , INF , (Peprotech) used 25ng/ml; LPS (Alexis) 
100ng/ml; Pam3Cys (Vinci Biochem) 2ug/ml according to the manufacture’s instructions.  
Tumor-conditioned media were prepared using  Human PT45 and PANC1 tumor cell lines, 
murine P815, MN-MCA1, PANC02, MCA-1 and MCA-2 tumor cell lines following M&M 
described in Solinas et al 2010 [59]. 
 
Macrophage  differentiation and polarization 
Human monocytes were obtained from normal blood donor buffy coats by two-step gradient 
centrifugation. PBMCs were isolated by Histopaque-1077 density gradient centrifugation 
(SIGMA). Separation of monocyte and T cells was obtained from PBMCs by Percoll density 
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gradient centrifugation (GE Healthcare). Residual T and B cells were removed from monocyte 
fraction by plastic adherence in serum free RPMI . Murine BM-derived monocytes were obtained 
from femurs of 8-week-old male healthy mice and cultured O/N in RPMI 10%FBS. Non-adherent 
cells were plated in various culture conditions following the experimental plan as described below.  
Macrophages and TC-Mφ were obtained by culturing 106/ml of human/murine monocytes for 6 
days in RPMI 1640 5% FBS without other additions or supplemented with 25 ng/ml of  
human/murine recombinant M-CSF or in the presence of 30% of tumor cell line supernatants. 
To obtain M1/M2 polarization we stimulated overnight M-CSF-differentiated macrophages  
with LPS (100 ng/ml) (PeproTech) and human/murine IFNγ (500 U/ml) (PeproTech) to obtain M1-
Mf and with human/murine IL-4 (20 ng/ml) (PeproTech) to obtain M2-Mf. All samples were 
collected under endotoxin-free conditions.  
 
 
Molecular biology 
 
Real-time RT-PCR 
Total RNA extraction from our samples was performed with pureZOL RNA isolation reagent 
(BIORAD). cDNA was synthesized by random priming from 2μg of total RNA with GeneAmp 
RNA PCR kit (Applied Biosystems), according to the manufacturer’s instructions. Real-Time PCR 
was performed using SYBR Green dye and 7900HT Fast Real Time PCR Systems (Applied 
Biosystems). The sequences of primer pairs specific for each gene (Invitrogen) were designed with 
Primer Express Software (Applied Biosystems). Experiments were performed in triplicate for each 
sample. mRNA was normalized to GAPDH mRNA by subtracting the cycle threshold (Ct) value of 
GAPDH mRNA from the Ct value of the gene (ΔCt). Fold difference (2^-ΔΔCt) was calculated by 
comparing ΔCt values. 
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Protein detection by Elisa 
To determine the production of human/murine Osteoactivin , tumor cell lines/macrophages 
supernatants were collected, centrifuged, filtered and stored at -20°. Proteins levels were measured 
by commercially available human/murine ELISA kits, according to the manufacture’s instructions 
(R&D Systems). Data were analyzed with SoftMax Pro 5.3 software. 
 
Bio-plex Protein Array system 
IL1β, IL10, IL17, IL13, CCL2, CCL3, CCL4, Eotaxin, TNF , were measured in duplicate into 
monocytes/macrophages supernatants using the Bio-plex Protein Array system (BioRad), according 
to the manufacturer instructions. Our assay (Bio-plex Pro Muose Cytokine Standard 23-plex, 
groupI) was customized to detect and quantify for each cytokine, eight standard points ranged from 
2.00 to 40.000 pg/ml and the minimum detectable dose was <10pg/ml. 
Data from the reaction are acquired using the Bio-Plex system, analysed and presented as 
fluorescence intensity (FI) and target concentration on Bio-Plex Manager software.  
 
Osteoactivin  cell transduction 
To assess Osteoactivin  functions in vitro we generated tumor cell lines stably over-expressing 
OA. We transduced MCA-OA- cell lines G2 and G3 with a lentiviral plasmid that allows to 
constitutively express endogenous OA. For this reason we exploited a plasmid previously 
generated in the laboratory in which the murine coding sequence of Gpnmb was cloned in frame 
with the fluorescent reporter mCherry under the CMV promoter in a lentiviral vector called OA-
mCherry pRRL-Sin, and as a control the empty vector containing only mCherry, named mCherry 
pRRL-Sin. Transduction of G2 and G3 MCA cell lines was performed generating viral particles 
with HEK293T cells transfected with Lipofectamine2000 (ThermoFisher Scientific) according to 
manufacturer’s instruction. Briefly, cells transfected with a ratio of 2:1:2 of packaging plasmid 
(pCMV-Delta 8.2), envelope plasmid (pVSV-G) and tranfer plasmid (mCherry pRRL-Sin or OA-
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mCherry pRRL-Sin) respectively, and after 24 hours the media was replaced. 48 hours after 
transfection, the replaced media containing viral particles was collected, centrifuged to pellet 
HEK293T cells, filtered through a 0,45μm-sized filter, and used to replace the media of 50% 
confluent MCA cell lines, while fresh media was added to transfected HEK293T cells to do repeat 
the transduction procedure. Cell lines generated were expanded 24 hours after the last transduction 
to assess Osteoactivin  expression by flow cytometry and ELISA as described.  
 
In vitro functional tests 
 
Cell adhesion assay 
Plates were coated with 2ug/ml of recombinant human Osteoactivin  or serum free RPMI 
(coating control) for 2 hrs at 37 °C and washed two times. Cells were then plated for adherence at 
37 °C for 90 minutes. Non-adherent cells were removed by carefully washing plates while adherent 
cells were fixed and stained with Diff-Quik (Medion Diagnostics) according to the manufacture’s 
instructions. Diff-Quik was rinsed out of the wells with water, and the plates were allowed to dry. 
Stained cells were counted considering 5 different areas. 
 
Cell migration assay 
Cell migration was evaluated using transwell system with 5 μm pore size in 24 well plate 
(Costar). 10
5
 cells were suspended in 200ul of medium and plated onto the membrane in the upper 
chamber; the lower chamber was filled with 600 ul of medium containing different concentrations 
(50-100 ug/ml) of recombinant OA (R&D). RPMI 1%FBS or recombinant CCL2 (100 ug/ml) were 
used respectively as negative and positive control. After 90 minutes of incubation we counted 
migrated cells contained into the lower chamber.  
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Flow cytometry 
 
To measure the expression of cell surface molecules, cells were were blocked using PBS 1% 
human/mouse serum and routinely stained and analyzed by flow cytometry on FACS Canto (BD 
Bioscience). For staining procedures, cells were washed and resuspended in FACS buffer. 
To analyzed the expression of stemness marker we used: PerCp-Rat CD45, Ecadherin- PE, B-
catenin FITC, CD47 APC, CD49b PE, CD 49e PE, CD61 FITC, CD41 BV450, CD51 PE, CD54 
Pacif Blue, CD34 FITC, CD117 PECy7, Sca1 PECy7, CD44 FITC, CD135 PE, RANK PE, CD138 
APC, CD71 FITC (BD Bioscience); Anti-mouse PE F4/80 (AbD Serotec); Pacific Blue-Rat CD11b 
(Biolegend).  Labeled cells were fixed in PBS-/- 1X 1% formalin. After staining procedures, 
acquisition was performed by FACS CantoII instrument (BD Biosciences) and analyzed by FACS 
Diva and FlowJo software version 6.1.1 (BD Biosciences). For SOX2 (ThermoFisher)  intracellular 
staining we used the BD Fixation/Permeabilization solution kit and Perm-wash to wash samples 
between various steps of the staining. Flow cytometry analysis was performed by FACS CantoTM 
instrument and FACS Diva software version 6.1.1 (BD Biosciences). 
 
Mouse tumor models 
Mice were used in compliance with national (4D.L.N.116, G.U., suppl. 40, 18-2-1992) and 
international law and policies (EEC Council Directive 86/609, OJ L 358, 1, 12-12-1987; NIH 
Guide for the Care and Use of Laboratory Animals, US National Research Council 1996). DBA/2J 
Gpnmb
+
 
 
were purchased
 
from the Jackson Laboratory (Bar Harbor, ME) and maintained and 
breaded at Charles River (Calco, Milano); DBA/2J mice of 8 weeks were directly purchased from 
Charles River. Tumors were induced by intraperitoneal or intramuscular injection of tumour cells; 
the number of injected cells is variable depending on the type of experiment. 
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Immunohistochemistry and immunofluorescence 
 
Paraffin embedded Murine tissues were cut at 3 um and put on superfrost slides. After dewaxing 
and rehydration, antigen unmasking were performed in decloaking chamber in DIVA buffer ( 
Biocare Medical) and with citrate buffer pH 6.00 in thermostatic bath (for Ki67). Endogenous 
peroxidases were blocked with 2% H202 for 20 minutes and then rodent block M were used to 
block unspecific binding sites. Sections were incubated with rat anti mouse CD68 1:100 (clone FA-
11 Hycult Biotechnology), rat anti mouse F4/80 1:400 (AbD Serotec), goat anti mouse CD31 
1:1000 (R&D Systems), rabbit anti mouse αSMA 1:300 (Biocare Medical) and rabbit anti mouse 
Ki67 1:400 (Cell Signaling). All the primary antibodies were incubated for 1 hour in humid 
chamber. As secondary antibody we used Rat on Mouse HRP polymer kit (Biocare Medical) for 
CD68 and F4/80, Goat on rodent HRP (Biocare Medical) for CD31 and MACH 1 Universal HRP-
Polymer Detection (Biocare Medical) for αSMA and Ki67. Reactions were developed with 3,3'-
Diaminobenzidine, DAB, (Biocare Medical), than counterstained with hematoxylin and mounted 
with Eukitt. 
For collagen, sections were cut at 3 um, put on non-polarized slides and after dewaxing and 
rehydration, Sirius red staining was performed.  
In each experiment 5-8 tumors/group were analyzed, results are the mean of immunoreactive 
areas in 4 slices for tumor. For CD31 results are expressed as mean of number of positive vessels 
per areas in 4 slices for tumor. The analyses were performed with Image Pro-Analyzer 7.0 (Media 
Cybernetics) on pictures at the same magnifications. 
 
Statistical analysis 
 
Statistical analysis was performed using a paired or unpaired Student’s t-test. P-values of less 
than 0.05 were considered significant.  
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